DK1027439T3 - Multivalente antigenbindende proteiner - Google Patents

Multivalente antigenbindende proteiner

Info

Publication number
DK1027439T3
DK1027439T3 DK98965654.1T DK98965654T DK1027439T3 DK 1027439 T3 DK1027439 T3 DK 1027439T3 DK 98965654 T DK98965654 T DK 98965654T DK 1027439 T3 DK1027439 T3 DK 1027439T3
Authority
DK
Denmark
Prior art keywords
multivalent antigen
binding proteins
methods
immunoassay
diagnosis
Prior art date
Application number
DK98965654.1T
Other languages
English (en)
Inventor
Leon Gerardus Joseph Frenken
Steven Howell
Adrianus Marinus Ledeboer
Cornelis Paul Eri Van Der Logt
Original Assignee
Bac Ip Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bac Ip Bv filed Critical Bac Ip Bv
Application granted granted Critical
Publication of DK1027439T3 publication Critical patent/DK1027439T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927Diagnostic contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK98965654.1T 1997-10-27 1998-10-27 Multivalente antigenbindende proteiner DK1027439T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97308538 1997-10-27
PCT/EP1998/006991 WO1999023221A2 (en) 1997-10-27 1998-10-27 Multivalent antigen-binding proteins

Publications (1)

Publication Number Publication Date
DK1027439T3 true DK1027439T3 (da) 2010-05-10

Family

ID=8229570

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98965654.1T DK1027439T3 (da) 1997-10-27 1998-10-27 Multivalente antigenbindende proteiner

Country Status (9)

Country Link
US (1) US6670453B2 (da)
EP (1) EP1027439B1 (da)
CN (1) CN1203178C (da)
AT (1) ATE461282T1 (da)
AU (1) AU2152299A (da)
BR (1) BR9813276A (da)
DE (1) DE69841562D1 (da)
DK (1) DK1027439T3 (da)
WO (1) WO1999023221A2 (da)

Families Citing this family (258)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1169453A1 (en) 1999-04-22 2002-01-09 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
WO2001007555A1 (en) 1999-07-27 2001-02-01 Unilever N.V. Bleaching detergent compositions
WO2001044301A1 (en) * 1999-11-29 2001-06-21 Unilever Plc Immobilized single domain antigen-binding molecules
EP1240298B1 (en) 1999-12-22 2007-10-31 Unilever N.V. Detergent compositions comprising benefit agents
WO2001046514A1 (en) 1999-12-22 2001-06-28 Unilever N.V. Method of treating fabrics and apparatus used therein
EP1246898B1 (en) 1999-12-22 2005-10-26 Unilever N.V. Method of treating fabrics
CA2394870A1 (en) 1999-12-22 2001-06-28 Unilever Plc Method of delivering a benefit agent
CA2394787A1 (en) * 1999-12-23 2001-07-05 Unilever Plc Bleaching detergent compositions
WO2001077342A1 (en) * 2000-04-11 2001-10-18 Genentech, Inc. Multivalent antibodies and uses therefor
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
JP2005289809A (ja) * 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20050037358A1 (en) * 2001-12-21 2005-02-17 Serge Muyldermans Method for cloning of variable domain sequences
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
ES2368733T3 (es) 2002-07-18 2011-11-21 Merus B.V. Producción recombinante de mezclas de anticuerpos.
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
WO2004015425A1 (en) 2002-08-07 2004-02-19 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
DK2316852T3 (da) * 2002-11-08 2014-06-16 Ablynx Nv Stabiliserede enkeltdomæne-antistoffer
US20060034833A1 (en) * 2002-11-08 2006-02-16 Els Beirnaert Single domain antibodies directed against interferron-gamma and uses therefor
EP1558650A2 (en) * 2002-11-08 2005-08-03 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
US6974860B2 (en) * 2002-12-30 2005-12-13 Kimberly-Clark Worldwide, Inc. Target recognizing binding agents
NZ540771A (en) * 2003-01-10 2009-05-31 Ablynx Nv Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
EP2395016A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
DE60334645D1 (de) * 2003-11-07 2010-12-02 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
EP1733233B1 (en) * 2004-03-30 2012-12-12 GE Healthcare Bio-Sciences Corp. Lateral flow format, materials and methods
JP2008500972A (ja) * 2004-05-14 2008-01-17 キリンファーマ株式会社 免疫グロブリンの精製方法
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
KR20070084069A (ko) 2004-10-08 2007-08-24 도만티스 리미티드 Tnfr1에 대한 단일 도메인 항체 및 이의 사용 방법
CA2589839C (en) * 2004-12-02 2016-04-05 Unilever N.V. Method for affinity purification
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
PL1836500T3 (pl) * 2005-01-14 2010-12-31 Ablynx Nv Sposoby i testy do rozróżniania między różnymi postaciami chorób i zaburzeń cechujących się małopłytkowością i/lub samoistną interakcją między czynnikiem von Willebranda (vWF) a płytkami krwi
MX363423B (es) 2005-05-18 2019-03-22 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
EP2444424B1 (en) 2005-05-20 2018-08-08 Ablynx N.V. Improved nanobodies tm for the treatment of aggregation-mediated disorders
DE102005023617A1 (de) * 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
US20100323905A1 (en) * 2005-09-23 2010-12-23 Academisch Ziekenhuis Leiden Vhh for the Diagnosis, Prevention and Treatment of Diseases Associated with Protein Aggregates
US20070269422A1 (en) * 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
CA2672965C (en) 2006-12-19 2018-02-06 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
CN101977654A (zh) * 2008-03-21 2011-02-16 埃博灵克斯股份有限公司 冯威勒布兰特因子特异性结合物及其应用方法
EP2947097A1 (en) 2008-04-07 2015-11-25 Ablynx N.V. Amino acid sequences directed against the Notch pathways and uses thereof
KR20110014607A (ko) 2008-04-29 2011-02-11 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
RU2010153578A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойными вариабельными доменами и их применение
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
SG192489A1 (en) 2008-07-08 2013-08-30 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
LT2334705T (lt) * 2008-09-26 2017-03-27 Ucb Biopharma Sprl Biologiniai produktai
KR20110079693A (ko) 2008-10-29 2011-07-07 와이어쓰 엘엘씨 단일 도메인 항원 결합 분자의 정제 방법
AU2009333791B2 (en) 2008-10-29 2013-04-04 Ablynx N.V. Formulations of single domain antigen binding molecules
ES2729320T3 (es) 2008-12-19 2019-10-31 Ablynx Nv Inmunización genética para producir inmunoglobulinas contra antígenos asociados a células tales como P2X7, CXCR7 o CXCR4
EP2387583B1 (en) 2009-01-14 2018-09-19 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
PT2424889E (pt) 2009-04-30 2015-11-12 Ablynx Nv Método de produção de anticorpos de domínio
HUE051430T2 (hu) 2009-07-10 2021-03-01 Ablynx Nv Eljárás variábilis domének elõállítására
RU2012112550A (ru) 2009-09-01 2013-10-10 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
PL2473528T3 (pl) 2009-09-03 2015-05-29 Ablynx Nv Stabilne formulacje polipeptydów i ich zastosowanie
WO2011047262A2 (en) 2009-10-15 2011-04-21 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2011045079A1 (en) 2009-10-15 2011-04-21 Intercell Ag Hepatitis b virus specific human antibodies
WO2011046218A1 (ja) * 2009-10-16 2011-04-21 株式会社カネカ 抗体を生産するハンゼヌラ・ポリモルファ、それを用いた抗体の生産方法、およびそれにより得られる抗体
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP3309176A1 (en) 2009-12-14 2018-04-18 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and therapeutic use
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
WO2011098518A2 (en) 2010-02-11 2011-08-18 Ablynx Nv Delivery of immunoglobulin variable domains and constructs thereof
PT2533761T (pt) 2010-02-11 2019-06-17 Ablynx Nv Métodos e composições para a preparação de aerossóis
MX2012013490A (es) 2010-05-20 2013-01-29 Ablynx Nv Materiales biologicos relacionados con her3.
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
PE20131412A1 (es) 2010-08-03 2014-01-19 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
ES2660895T3 (es) 2010-10-29 2018-03-26 Ablynx N.V. Método para la producción de dominios variables individuales de inmunoglobulina
EP2638068B1 (en) 2010-11-08 2018-12-26 Novartis AG Cxcr2 binding polypeptides
WO2012130872A1 (en) 2011-03-28 2012-10-04 Ablynx Nv Method for producing solid formulations comprising immunoglobulin single variable domains
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9534039B2 (en) 2011-05-09 2017-01-03 Ablynx N.V. Method for the production of immunoglobulin single variable domains
PT2723771T (pt) 2011-06-23 2019-12-11 Ablynx Nv Proteínas de ligação à albumina sérica
DK2747782T3 (da) 2011-09-23 2018-04-23 Ablynx Nv Langvarig inhibering af interleukin-6-medieret signaloverførsel
CN106046161B (zh) 2011-09-30 2019-09-13 埃博灵克斯股份有限公司 与C-Met相关的生物物质
US20150056182A1 (en) 2011-11-30 2015-02-26 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
MX2014008101A (es) 2011-12-30 2014-09-25 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17.
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
CA2874721A1 (en) 2012-05-30 2013-12-05 Tomoyuki Igawa Target tissue-specific antigen-binding molecule
US11339208B1 (en) 2012-05-31 2022-05-24 United States Of America As Represented By The Secretary Of The Air Force Camelidae single-domain antibodies against Yersinia pestis and methods of use
WO2014071074A2 (en) 2012-11-01 2014-05-08 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
KR20210130260A (ko) 2013-04-02 2021-10-29 추가이 세이야쿠 가부시키가이샤 Fc영역 개변체
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
CN105980557B (zh) 2013-12-04 2020-04-07 中外制药株式会社 抗原结合能力根据化合物的浓度而变化的抗原结合分子及其文库
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CR20160425A (es) 2014-03-14 2017-05-26 Novartis Ag Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas
ES2939760T3 (es) 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
SG11201609707WA (en) 2014-07-01 2017-01-27 Pfizer Bispecific heterodimeric diabodies and uses thereof
CN112481283A (zh) 2014-07-21 2021-03-12 诺华股份有限公司 使用cd33嵌合抗原受体治疗癌症
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
JP7054622B2 (ja) 2014-07-21 2022-04-14 ノバルティス アーゲー ヒト化抗bcmaキメラ抗原受容体を使用した癌の処置
US20170209492A1 (en) 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
TW202140557A (zh) 2014-08-19 2021-11-01 瑞士商諾華公司 使用cd123嵌合抗原受體治療癌症
KR102590396B1 (ko) 2014-09-17 2023-10-19 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
ES2952717T3 (es) 2014-10-14 2023-11-03 Novartis Ag Moléculas de anticuerpos contra PD-L1 y usos de las mismas
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
ES2772348T3 (es) 2014-12-19 2020-07-07 Ablynx Nv Dímeros de Nanobody con uniones cisteína
JP6895421B2 (ja) 2015-03-31 2021-06-30 ブイエイチスクエアード リミテッド ポリペプチド
JP6929786B2 (ja) 2015-04-02 2021-09-01 アブリンクス エン.ヴェー. 強力な抗hiv活性を有する二重特異性cxcr4−cd4ポリペプチド
ES2923894T3 (es) 2015-04-08 2022-10-03 Novartis Ag Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CN107847559B (zh) 2015-05-13 2022-07-01 埃博灵克斯股份有限公司 基于cd3反应性的t细胞募集多肽
SI3294768T1 (sl) 2015-05-13 2019-11-29 Ablynx Nv Polipeptidi, ki rekrutirajo celice T, na osnovi reaktivnosti TCR alfa/beta
CN111234027A (zh) * 2015-05-21 2020-06-05 哈普恩治疗公司 三特异性结合蛋白质及使用方法
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗vegf、pdgf及/或其受體之結合蛋白
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
NO2768984T3 (da) 2015-11-12 2018-06-09
WO2017080850A1 (en) 2015-11-13 2017-05-18 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains
CN114605530A (zh) 2015-11-18 2022-06-10 埃博灵克斯股份有限公司 改进的血清白蛋白结合剂
EP3377527A1 (en) 2015-11-18 2018-09-26 Merck Sharp & Dohme Corp. Ctla4 binders
BR112018010084A2 (pt) 2015-11-18 2018-11-13 Merck Sharp & Dohme ligantes de pd1 e/ou lag3
EP3932945A1 (en) 2015-11-27 2022-01-05 Ablynx NV Polypeptides inhibiting cd40l
KR20180094977A (ko) 2015-12-17 2018-08-24 노파르티스 아게 c-Met 억제제와 PD-1에 대한 항체 분자의 조합물 및 그의 용도
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
EP3405492B1 (en) 2016-01-21 2020-10-21 Novartis AG Multispecific molecules targeting cll-1
CA3016287A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
ES2944607T3 (es) 2016-04-15 2023-06-22 Novartis Ag Composiciones y métodos para la expresión selectiva de receptores quiméricos para el antígeno
AU2017259876A1 (en) 2016-05-02 2018-10-25 Ablynx Nv Treatment of RSV infection
JP7101621B2 (ja) 2016-05-20 2022-07-15 ハープーン セラピューティクス,インク. 単一ドメイン血清アルブミン結合タンパク質
EA201892693A1 (ru) 2016-05-20 2019-04-30 Харпун Терапьютикс, Инк. Белки, содержащие одноцепочечный вариабельный фрагмент, связывающийся с cd3
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3464375A2 (en) 2016-06-02 2019-04-10 Novartis AG Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
CN110461315A (zh) 2016-07-15 2019-11-15 诺华股份有限公司 使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征
BR112019001570A2 (pt) 2016-07-28 2019-07-09 Novartis Ag terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1
KR20190036551A (ko) 2016-08-01 2019-04-04 노파르티스 아게 Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
US10525083B2 (en) 2016-10-07 2020-01-07 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
KR20240076829A (ko) 2016-11-16 2024-05-30 아블린쓰 엔.브이. Cd123 및 tcr 알파/베타에 결합할 수 있는 t 세포 동원 폴리펩티드
JP6812551B2 (ja) 2016-11-23 2021-01-13 ハープーン セラピューティクス,インク. 前立腺特異的膜抗原結合タンパク質
CA3044729A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
KR20240001271A (ko) 2016-12-07 2024-01-03 아블린쓰 엔.브이. 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인
EP3571224B1 (en) 2017-01-17 2024-08-07 Ablynx NV Improved serum albumin binders
US11414481B2 (en) 2017-01-17 2022-08-16 Ablynx N.V. Serum albumin binders
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
WO2018160731A1 (en) 2017-02-28 2018-09-07 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
IL300964A (en) 2017-05-12 2023-04-01 Harpoon Therapeutics Inc mesothelin binding proteins
KR20200026810A (ko) 2017-05-12 2020-03-11 하푼 테라퓨틱스, 인크. Msln 표적화 삼중 특이적 단백질 및 사용 방법
CN111032695B (zh) 2017-06-02 2024-06-25 默克专利股份有限公司 结合adamts的免疫球蛋白
TW202413408A (zh) 2017-06-02 2024-04-01 比利時商艾伯林克斯公司 結合聚集蛋白聚糖之免疫球蛋白
MX2019014397A (es) 2017-06-02 2020-02-10 Merck Patent Gmbh Polipeptidos que enlazan adamts5, mmp13 y agrecano.
JP2020521804A (ja) 2017-06-02 2020-07-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Mmp13結合免疫グロブリン
US11312783B2 (en) 2017-06-22 2022-04-26 Novartis Ag Antibody molecules to CD73 and uses thereof
WO2019006007A1 (en) 2017-06-27 2019-01-03 Novartis Ag POSOLOGICAL REGIMES FOR ANTI-TIM3 ANTIBODIES AND USES THEREOF
SG11201913137VA (en) 2017-07-11 2020-01-30 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
CA3067247A1 (en) 2017-07-11 2019-01-17 Alexion Pharmaceuticals, Inc. Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
CN111108126B (zh) 2017-07-19 2024-04-26 非营利性组织佛兰芒综合大学生物技术研究所 血清白蛋白结合剂
JP2020527572A (ja) 2017-07-20 2020-09-10 ノバルティス アーゲー 抗lag−3抗体の投薬量レジメンおよびその使用
EA202090739A1 (ru) 2017-10-13 2020-09-07 Харпун Терапьютикс, Инк. Белки, связывающие антиген созревания в-клеток
PE20201183A1 (es) 2017-10-13 2020-11-03 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
CA3081602A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
CA3079793A1 (en) 2017-12-22 2019-06-27 Argenx Bvba Bispecific antigen binding construct
US20210038659A1 (en) 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
JP2021525243A (ja) 2018-05-21 2021-09-24 コンパス セラピューティクス リミテッド ライアビリティ カンパニー Nk細胞による標的細胞の殺傷を増進するための組成物および方法
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
AU2019284911A1 (en) 2018-06-13 2020-12-17 Novartis Ag BCMA chimeric antigen receptors and uses thereof
BR112020026033A2 (pt) 2018-06-19 2021-03-23 Atarga, Llc moléculas de anticorpo para complementar o componente 5 e usos das mesmas
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
BR112021005769A2 (pt) 2018-09-25 2021-07-06 Harpoon Therapeutics Inc proteínas de ligação a dll3 e métodos de uso
AU2019379576A1 (en) 2018-11-13 2021-06-03 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
MX2021007391A (es) 2018-12-20 2021-09-23 Novartis Ag Regimenes de baja dosis extendida para inhibidores de mdm2.
US20240245670A1 (en) 2018-12-20 2024-07-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP3924054A1 (en) 2019-02-15 2021-12-22 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
BR112021015672A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
EP3927371A1 (en) 2019-02-22 2021-12-29 Novartis AG Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
EP3943108A4 (en) 2019-03-19 2023-01-04 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE CONTAINING AN ANTIGEN-BINDING DOMAIN WHOSE ANTIGEN-BINDING ACTIVITY IS ALTERED DEPENDING ON THE MTA, AND BANK FOR OBTAINING SUCH ANTIGEN-BINDING DOMAIN
MA55519A (fr) 2019-03-29 2022-02-09 Atarga Llc Anticorps anti-fgf23
CA3144567A1 (en) 2019-06-21 2020-12-24 Scott Crowe Polypeptides
WO2020254826A1 (en) 2019-06-21 2020-12-24 Vhsquared Limited Polypeptides
EP3986570A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Compositions
AU2020370832A1 (en) 2019-10-21 2022-05-19 Novartis Ag TIM-3 inhibitors and uses thereof
TW202128166A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 組合療法
BR112022010206A2 (pt) 2019-11-26 2022-11-29 Novartis Ag Receptores de antígeno quiméricos e usos dos mesmos
CN114981300A (zh) 2019-12-06 2022-08-30 艾伯霖克斯公司 包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽
AU2020397210A1 (en) 2019-12-06 2022-07-28 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting TNFa and OX40L
US20210188965A1 (en) 2019-12-09 2021-06-24 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp
WO2021123902A1 (en) 2019-12-20 2021-06-24 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
US20230058489A1 (en) 2020-01-17 2023-02-23 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
EP4090762A1 (en) 2020-01-17 2022-11-23 Becton, Dickinson and Company Methods and compositions for single cell secretomics
IL295448A (en) 2020-02-21 2022-10-01 Harpoon Therapeutics Inc flt3 binding proteins and methods of use
JP2023515211A (ja) 2020-02-27 2023-04-12 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
BR112022018364A2 (pt) 2020-03-30 2022-11-08 Ablynx Nv Método para produção e purificação de domínios variáveis únicos de imunoglobulina multivalente
MX2022015852A (es) 2020-06-23 2023-01-24 Novartis Ag Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
PE20231093A1 (es) 2020-07-16 2023-07-18 Novartis Ag Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4217390A1 (en) 2020-09-25 2023-08-02 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
WO2022097065A2 (en) 2020-11-06 2022-05-12 Novartis Ag ANTIBODY Fc VARIANTS
CN116635062A (zh) 2020-11-13 2023-08-22 诺华股份有限公司 使用表达嵌合抗原受体(car)的细胞的组合疗法
EP4256067A2 (en) 2020-12-04 2023-10-11 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
US11897951B2 (en) 2020-12-18 2024-02-13 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
KR20230123495A (ko) 2020-12-18 2023-08-23 아블린쓰 엔.브이. 글리피칸-3 및 t세포 수용체를 표적으로 하는 면역글로불린단일 가변 도메인을 포함하는 폴리펩티드
WO2022129637A1 (en) 2020-12-18 2022-06-23 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
US20240141060A1 (en) 2021-01-29 2024-05-02 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
US20240228593A9 (en) 2021-02-19 2024-07-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CN113583125B (zh) * 2021-07-09 2022-09-20 苏州晟济药业有限公司 抗体以及包含其的结合剂、免疫吸附材料及其应用
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN118302818A (zh) 2021-11-22 2024-07-05 阿布林克斯有限公司 获得目标多价免疫球蛋白单可变结构域的序列信息
AU2022409733A1 (en) 2021-12-17 2024-08-01 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123
WO2023150778A1 (en) 2022-02-07 2023-08-10 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
WO2023170553A1 (en) 2022-03-07 2023-09-14 Takeda Pharmaceutical Company Limited Affinity chromatographic production of clinical human igg products
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023240156A1 (en) 2022-06-08 2023-12-14 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
US20240109965A1 (en) 2022-06-14 2024-04-04 Ablynx N.V. Immunoglobulin single variable domains targeting t cell receptor
WO2024017915A1 (en) 2022-07-18 2024-01-25 Ablynx N.V. Cx3cr1-binding compounds, uses thereof and related methods
US20240132624A1 (en) 2022-07-27 2024-04-25 Ablynx N.V. Polypeptides binding to a specific epitope of the neonatal fc receptor
WO2024030976A2 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier
WO2024068944A1 (en) 2022-09-30 2024-04-04 Sanofi Anti-cd28 antibodies
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
US20240209107A1 (en) 2022-12-19 2024-06-27 Sanofi Cd28/ox40 bispecific antibodies
WO2024137731A2 (en) 2022-12-21 2024-06-27 Genzyme Corporation Anti‑pd‑1×4‑1bb binding proteins
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
WO2024168061A2 (en) 2023-02-07 2024-08-15 Ayan Therapeutics Inc. Antibody molecules binding to sars-cov-2
WO2024168279A2 (en) 2023-02-10 2024-08-15 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen (psma) and methods for making and using the same
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
CA2122732C (en) 1991-11-25 2008-04-08 Marc D. Whitlow Multivalent antigen-binding proteins
DE69329974T2 (de) * 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
SG55079A1 (en) * 1992-12-11 1998-12-21 Dow Chemical Co Multivalent single chain antibodies
DE69427974T2 (de) 1993-04-29 2001-12-06 Unilever N.V., Rotterdam Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
JP2000508892A (ja) 1996-04-04 2000-07-18 ユニリーバー・ナームローゼ・ベンノートシャープ 多価および多特異的抗原結合タンパク

Also Published As

Publication number Publication date
ATE461282T1 (de) 2010-04-15
CN1203178C (zh) 2005-05-25
EP1027439A2 (en) 2000-08-16
WO1999023221A2 (en) 1999-05-14
US6670453B2 (en) 2003-12-30
WO1999023221A3 (en) 1999-10-07
CN1278300A (zh) 2000-12-27
US20030092892A1 (en) 2003-05-15
EP1027439B1 (en) 2010-03-17
AU2152299A (en) 1999-05-24
BR9813276A (pt) 2000-08-22
DE69841562D1 (de) 2010-04-29

Similar Documents

Publication Publication Date Title
DK1027439T3 (da) Multivalente antigenbindende proteiner
WO2000024884A3 (en) Antigen-binding proteins comprising a linker which confers restricted conformational flexibility
HRP20000714B1 (en) NOVEL CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
FR08C0006I2 (fr) Anticorps monoclonaux humains contre le recepteur du facteur de croissance epidermique
ATE440868T1 (de) Monoklonaler antikírper gegen ein prion protein und dessen verwendung zum nachweis von prionen
WO2001090192A3 (en) Bispecific immunoglobulin-like antigen binding proteins and method of production
DE69429925D1 (de) METHODE ZUR BINDUNG VON MATERIAL AN DAS Beta-AMYLOID-PEPTID
DK1233987T3 (da) Immobiliserede enkelt-domæne antigenbindende molekyler
DK0975771T3 (da) Fusionsproteiner af TGF-beta-receptortype II og immunoglobulins konstante region
ATE187494T1 (de) Multivalente einkettige antikörper
BR9507594B1 (pt) anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteìna recombinante.
FI965032A0 (fi) Interleukiini-5-spesifisiä yhdistelmä-vasta-aineita
CA2469833A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
ATE545703T1 (de) Multivalentes zielbindendes protein
DK0727435T3 (da) Monoklonale antistoffer (MAK) mod tumorassocierede antigener, deres fremstilling og anvendelse
ATE260977T1 (de) Immunoglobulin-bindende proteine